Crescent Biopharma, Inc. (CBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Crescent Biopharma reported revenue of $10.8M. Net income was -$153.9M (a -1419.6% net margin). Operating margin was -1407.5%. Operating activities generated -$71.5M of cash, leaving -$72.4M of free cash flow. At fiscal year end, Crescent Biopharma held $240.3M in total assets against $37.3M in total liabilities, including $213.2M of cash and equivalents.
Open the full interactive Crescent Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Crescent Biopharma Key Stats
| Share Price | $12.91 |
|---|---|
| 52-Week Range | $8.94 – $26.98 |
| Shares Outstanding | 645,223 (basic, 2025 Q1) |
Crescent Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.2M | $75,000 | $10,000 | $0 | $10.8M |
| Operating Income | -$51.5M | -$63.4M | -$47.4M | -$39.3M | -$40.0M | -$152.6M |
| Pre-Tax Income | -$51.0M | -$63.4M | -$46.7M | -$36.9M | -$37.9M | -$151.9M |
| Income Tax | — | — | — | — | — | $2.0M |
| Net Income | -$51.0M | -$63.4M | -$46.7M | -$36.9M | -$37.9M | -$153.9M |
| Diluted EPS | -$112.00 | -$123.00 | -$89.00 | -$58.00 | -$59.00 | — |
Crescent Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $10.8M | $1.0M | $0 |
| Net Income | -$24.6M | -$105.2M | -$23.3M | -$24.8M |
Crescent Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $137.0M | $90.3M | $47.9M | $41.8M | $10.7M | $213.2M |
| Current Assets | $138.3M | $90.8M | $50.7M | $43.8M | $11.1M | $236.7M |
| Total Assets | $142.8M | $94.3M | $51.8M | $45.3M | $11.1M | $240.3M |
| Current Liabilities | $12.4M | $11.8M | $8.9M | $6.8M | $5.8M | $36.1M |
| Total Liabilities | $14.6M | $12.7M | $8.9M | $6.9M | $5.8M | $37.3M |
| Shareholders' Equity | $128.2M | $81.6M | $42.9M | $38.4M | $5.3M | $203.0M |
Crescent Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$39.2M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$71.5M |
| Cash From Investing | -$68,507 | -$14,943 | -$84,191 | -$21,394 | $20,028 | -$72.9M |
| Cash From Financing | $18.1M | $10.7M | $4.2M | $28.8M | $5,398 | $323.0M |
| Free Cash Flow | -$39.3M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$72.4M |
Figures from Crescent Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Crescent Biopharma financials page for every line item.
Crescent Biopharma Company Profile
| Ticker | CBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001253689 |
Frequently Asked Questions
What was Crescent Biopharma's revenue in fiscal 2025?
Crescent Biopharma (CBIO) reported revenue of $10.8M for fiscal 2025.
What is Crescent Biopharma's annual revenue history?
Crescent Biopharma's annual revenue by fiscal year: 2020: $10.2M; 2021: $1.2M; 2022: $75,000; 2023: $10,000; 2024: $0; 2025: $10.8M.
What was Crescent Biopharma's net income in fiscal 2025?
Crescent Biopharma reported net income of -$153.9M for fiscal 2025.
How much free cash flow did Crescent Biopharma generate in fiscal 2025?
Crescent Biopharma generated -$72.4M of free cash flow in fiscal 2025.
What was Crescent Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Crescent Biopharma reported revenue of $0.
How many shares of Crescent Biopharma are outstanding?
Crescent Biopharma reported a weighted average of 645,223 basic shares outstanding in 2025 Q1.
When does Crescent Biopharma's fiscal year end?
Crescent Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Crescent Biopharma headquartered?
Crescent Biopharma lists its business address in Waltham, Massachusetts in its SEC filings.